These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 7430351)

  • 41. ["Hypo-alpha-lipoproteinemia" (Tangier-disease) (author's transl)].
    Vivell O; Gusek W; Greten H; Hannemann Th
    Klin Padiatr; 1976 Jan; 188(1):82-7. PubMed ID: 176501
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma high-density lipoprotein metabolism in subjects with primary hypertriglyceridaemia: altered metabolism of apoproteins AI and AII.
    Rao SN; Magill PJ; Miller NE; Lewis B
    Clin Sci (Lond); 1980 Nov; 59(5):359-67. PubMed ID: 7428302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. De novo development of hypercholesterolemia and elevated high-density lipoprotein cholesterol: apoprotein A-I ratio in patients with chronic renal failure following kidney transplantation.
    Kobayashi N; Okubo M; Marumo F; Uchida H; Endo T; Nakamura H
    Nephron; 1983; 35(4):237-40. PubMed ID: 6417553
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Altered apoprotein composition of HDL2 and HDL3 in chronic alcoholics.
    Avogaro P; Cazzolato G; Belussi F; Bittolo Bon G
    Artery; 1982; 10(5):317-28. PubMed ID: 7181675
    [No Abstract]   [Full Text] [Related]  

  • 45. Musca domestica larval lipoprotein.
    de Bianchi AG; Capurro Mde L
    Arch Insect Biochem Physiol; 1991; 17(1):15-27. PubMed ID: 1932777
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of lipids, apoproteins and associated enzyme activities between diabetic and nondiabetic end-stage renal disease.
    Sakurai T; Oka T; Hasegawa H; Igaki N; Miki S; Goto T
    Nephron; 1992; 61(4):409-14. PubMed ID: 1501737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levels of cholesterol, triglyceride, high-density lipoprotein-cholesterol and apoprotein-HDL in an Australian rural population.
    Marsarei JR; Lynch WJ; Robertson K; Curnow DH; Fullerton R
    Pathology; 1981 Oct; 13(4):725-34. PubMed ID: 7335379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HDL and its subfractions in patients with chronic liver diseases.
    Kajiyama G; Takata K; Horiuchi I; Oyamada K; Miyoshi A
    Hiroshima J Med Sci; 1981 Dec; 30(4):273-9. PubMed ID: 6765678
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of ascorbic acid on total and high density lipoprotein cholesterol of plasma in normal human subjects.
    Joshi VD; Joshi LN; Gokhale LV
    Indian J Physiol Pharmacol; 1981; 25(4):348-50. PubMed ID: 7341462
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Variations in paper electrophoretic serum lipoprotein patterns in healthy subjects.
    Buckley GC; Little JA; Csima A; Koenig E; Yano R; Sullivan K
    Can Med Assoc J; 1970 May; 102(9):943-5. PubMed ID: 5538493
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein C-III.
    Holdsworth G; Stocks J; Dodson P; Galton DJ
    J Clin Invest; 1982 Apr; 69(4):932-9. PubMed ID: 7076853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma-triglycerides do not regulate high-density lipoprotein concentrations.
    Herbert PN; Henderson LO
    Lancet; 1979 Jun; 1(8131):1368-70. PubMed ID: 87831
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dialysis Modalities and HDL Composition and Function.
    Holzer M; Schilcher G; Curcic S; Trieb M; Ljubojevic S; Stojakovic T; Scharnagl H; Kopecky CM; Rosenkranz AR; Heinemann A; Marsche G
    J Am Soc Nephrol; 2015 Sep; 26(9):2267-76. PubMed ID: 25745027
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs.
    Franceschini G; Poli A; Catapano AL; Gatti E; Sirtori M; Gianfranceschi G; Sirtori CR
    Atherosclerosis; 1981; 40(3-4):245-55. PubMed ID: 7332603
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased level of the complement C3 protein in endogenous hypertriglyceridemia.
    Uza G; Cristea A; Cucuianu MP
    J Clin Lab Immunol; 1982 Jun; 8(2):101-5. PubMed ID: 7108936
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravascular metabolism of an artificial transporter of triacylglycerols. Alterations of serum lipoproteins resulting from total parenteral nutrition with Intralipid.
    Untracht SH
    Biochim Biophys Acta; 1982 Apr; 711(1):176-92. PubMed ID: 6802185
    [No Abstract]   [Full Text] [Related]  

  • 57. Novel apoprotein A-I-containing lipoprotein produced by a human hepatoma-derived cell line HuH-7.
    Yamamoto T; Suda M; Moriwaki Y; Takahashi S; Higashino K
    Biochim Biophys Acta; 1990 Oct; 1047(1):49-56. PubMed ID: 2174265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of high density lipoproteins in human cholestasis.
    Arnesjö B; Danielsson B; Ekman R; Johansson BG; Petersson BG
    Scand J Clin Lab Invest; 1977 Nov; 37(7):587-97. PubMed ID: 202013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure of human high density lipoprotein reassembled in vitro. Radioimmunoassay studies.
    Schonfeld G; Pfleger B; Roy R
    J Biol Chem; 1975 Oct; 250(19):7934-50. PubMed ID: 170277
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Apoprotein A and high density lipoprotein cholesterol levels in ischemic heart disease.
    Hamada N
    Jpn Circ J; 1980 Jul; 44(7):487-94. PubMed ID: 6772823
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.